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Abstract: Bioluminescence imaging (BLI) has been applied in gene therapy and research to screen 
for transgene expression, progression of infection, tumor growth and metastasis, and transplantation. 
It enables real-time and relatively noninvasive localization and serial quantification of biological 
processes in experimental animals. In diabetes research, BLI has been employed for the quantification 
of β-cell mass, monitoring of islet graft survival after transplantation, and detection of reporter gene 
expression. Here, we explore the use of BLI in a transgenic mouse expressing luciferase under the 
control of the mouse insulin 1 promoter (MIP-Luc-VU). A previous report on MIP-Luc-VU mice showed 
luminescence intensities emitted from the islets correlated well with the number of islets in vitro and 
in vivo. In this study, we showed MIP-Luc-VU mice fed a high fat diet for 8 weeks gave rise to a 
greater bioluminescent signal than mice fed a regular diet for the same period of time. Conversely, 
there was a strong reduction in the signal observed in diabetic Mafa-deficient/Mafk-transgenic mutant 
mice and streptozotocin-treated mice, reflecting the loss of β-cells. Furthermore, we were able to 
monitor fetal β-cell genesis in MIP-Luc-VU mice during the late gestational stage in a noninvasive 
and repetitive manner. In summary, we show that bioluminescence imaging of mice expressing a 
β-cell specific reporter allows detection of changes in β-cell mass and visualization of fetal β-cell 
neogenesis in uteri.
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Introduction
insulin is a 51-amino acid peptide hormone exclu-
sively produced by pancreatic β-cells that plays a piv-
otal role in the maintenance of glucose homeostasis. 
Postnatal growth of the β-cell mass in mice derives from-
proliferation of preexisting β-cells rather than de novo 
differentiation of pluripotent stem cells [7]. in rodents, 
the number of β cells increases during the first year of 
life to compensate for increased metabolic needs [3]. 
However, the rate of β-cell replication decreases with 
age from ~20% per day in pups to ~10% per day at wean-
ing and 2–5% per day in young adults [3].
Type 1 or insulin-dependent diabetes mellitus results 
from a deficiency in insulin due to autoimmune-mediat-
ed destruction of β-cells [2]. In type 2 or non-insulin-
dependent diabetes, which is characterized by chronic 
insulin resistance and a progressive decline in β-cell 
function, a decrease in the β-cell mass also contributes 
to disease initiation and progression [4]. Therefore, es-
timation of β-cell mass in both types of diabetes using 
positron emission tomography (PeT) or nuclear mag-
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netic resonance imaging (mRi) could facilitate the study 
of disease pathophysiology and the effects of therapeu-
tic interventions [10, 20].
The conventional method to assess β-cell mass in ex-
perimental animals involves analysis of histological 
sections over time. Recent progress in the development 
of noninvasive methods to monitor changes in β-cell 
mass has provided a powerful complement to this con-
ventional assay. an increasing number of studies have 
shown that optical techniques such as bioluminescence 
imaging (BLI) can be used to quantify β-cell mass. The 
bioluminescent signal from the islets expressing a lucif-
erase reporter has been shown to correlate with β-cell 
mass and can therefore serve as an indicator of changes 
in β-cell mass [8, 13].
a previous report on luminescence reporter mice that 
express luciferase under the control of the mouse insulin 
promoter [FVB/N-Tg(Ins1-luc)VUPwrs/J, named miP-
Luc-Vu] showed luminescence intensities emitted from 
the islets correlated well with the number of islets in 
vitro and in vivo through islet transplantation into im-
munocompromised mice [21]. in this study, we measured 
the change in BLi signal intensity in response to aug-
mentation or diminution of β-cell mass in MIP-Luc-VU 
mice. we also examined whether BLi could be used for 
identification of fetal β-cell genesis in uteri. We found 
that BLI could detect the increase in β-cell mass result-
ing from an 8-week high-fat diet. Furthermore, BLI 
could detect the reduction in β-cell mass resulting from 
streptozotocin (STZ) administration or generation of 
miP-Luc-Vu mice that were Mafa-deficient (ICR-Ma-
fasm1Staka/Mafasm1Staka, Mafa−/−) on a Mafk-transgenic 
[icR-Tg(RIP-Mafk)1Staka, Mafk+] background (Mafa−/−
Mafk+). The transport of STZ into β cells by a glucose 
transporter, glut2, leads to increased production of reac-
tive oxygen species and cell death [5]. mafa is a tran-
scription factor belonging to the large maf family and is 
necessary for functional β-cell maturation through acti-
vation of the expression of Ins1, Ins2, Pdx1, Glut2, and 
Beta2 [1, 23]. mafk is a transcription factor belonging 
to the small maf family, whose members function as 
transcriptional repressors or form heterodimeric com-
plexes that serve as transcriptional coactivators owing 
to a lack of distinct activation domains. double mutant 
Mafa−/−Mafk+ mice exhibit nearly complete lack of 
β-cells at birth and present with early onset of diabetes 
accompanied by a kidney disease that resembles human 
diabetic nephropathy [17]. Both models result in severe 
β-cell loss and dysfunction and insulin deficiency. Fi-
nally, we showed fetal β-cell neogenesis could be de-
tected in uteri by BLi of pregnant wild-type mice that 
had been mated with miP-Luc-Vu mice.
Materials and Methods
Animals
Transgenic mice expressing luciferase under the con-
trol of the mouse insulin 1 promoter [FVB/N-Tg(Ins1-
luc)VUPwrs/J, Stock number 007800, MIP-Luc-VU] 
were purchased from The Jackson Laboratory (Bar har-
bor, me, uSa) [21]. all mice used in the study was 
backcrossed to Jcl:icR (cLea Japan, Tokyo, Japan) 
more than four generations [icR-Tg(Ins1-luc)VUPwrs/J]. 
Mafa−/− and Mafk+ mice were generated as described 
previously [18, 23]. All mice were maintained in spe-
cific pathogen-free conditions in the Laboratory Animal 
Resource center, university of Tsukuba. all experiments 
were performed according to the guide for the care and 
use of Laboratory animals at the university of Tsukuba 
and approved by the institutional Review Board of the 
university.
Bioluminescence imaging of MIP-Luc-VU mice
To detect bioluminescence of miP-Luc-Vu mice using 
an iViS Spectrum (caliper, alameda, ca, uSa), 50 µg 
of d-luciferin (Promega, madison, wi, uSa) per kilo-
gram of body weight was injected intraperitoneally (i.p.) 
or intravenously (i.v.) and imaged for 1 min 10 min 
later. equal area regions of interest (ROi) were centered 
over the bioluminescent region, and bioluminescence 
intensity was quantified as the sum of all detected photon 
counts per second within an ROi by using the Living 
image software (caliper). The Mafa−/−miP-Luc-Vu 
mice were obtained from interbreeding of icR-Ma-
fasm1Staka/Mafa+ (Mafa+/−) and Mafa+/−miP-Luc-Vu 
mice, and Mafa−/−Mafk+miP-Luc-Vu mice were gener-
ated from interbreeding of Mafa+/−Mafk+ mice and 
Mafa+/−MIP-Luc-VU mice. For imaging of fetal β-cell 
development, pregnant wild-type icR mice fertilized by 
miP-Luc-Vu mice were injected with 5 µg per weight 
of d-luciferin intravenously at embryonic days (e) 14.5, 
16.5, and 18.5 and imaged for 3 min 20–30 min later.
High-fat diet
male miP-Luc-Vu mice were fed either a control 
regular diet (Rd) or a high-fat diet (hFd) consisting 
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62.2% fat, 19.6% carbohydrates, and 18.2% protein on 
a calorie basis (Oriental Yeast, Tokyo, Japan) for 8 weeks 
beginning at 6 weeks of age. Fasting blood glucose lev-
els in both groups of mice were measured using a dRi-
CHEM 3500 (Fujifilm, Tokyo, Japan).
Histological analysis
Mice fed either a RD or a HFD for 8 weeks were 
euthanized, and pancreatic tissues were removed. Tissues 
fixed in 10% formalin were embedded in paraffin, and 
each section was stained with hematoxylin and eosin. 
islet area and total pancreas area of randomly chosen 
cross sections were measured using a Biorevo BZ-9000 
microscope (keyence, Osaka, Japan) and the BZ-ii 
analyzer software (keyence). Relative islet area (%) 
was determined as the islet:pancreas ratio. For immuno-
histochemical analyses, tissue sections were incubated 
with guinea pig anti-insulin antibody (abcam, cam-
bridge, ma, uSa) and rabbit anti-glucagon antibody 
(millipore, Billerica, ma, uSa), anti-somatostatin an-
tibody (invitrogen, camarillo, ca, uSa), and anti-
pancreatic polypeptide antibody (dako, glostrup, den-
mark) for 8 h at 4°C. The antigens were visualized using 
appropriate secondary antibodies conjugated with al-
exa488 and Alexa594 with nuclear staining using di-
amidino-2-phenylindole (daPi) (invitrogen).
Diabetes induction
MIP-Luc-VU mice at 8 weeks of age were rendered 
diabetic by an intraperitoneal injection of streptozotocin 
(STZ, Sigma, St. Louis, mO, uSa) at a dose of 200 mg/
kg body weight in 0.1 m citrate buffer (ph 4.5).
Statistical analysis
Results are expressed as means ± standard error of the 
mean. Statistical significance was calculated by paired 
or unpaired Student’s t-test. P values of less than 0.05 
were considered significant.
Results
Noninvasive monitoring of changes in β-cell mass
Male MIP-luc-VU mice fed a HFD for 8 weeks de-
veloped hyperglycemia (Rd and hFd: 95 ± 7.2 and 157 
± 18.4 mg/dl, respectively, n=7 in each group, P=0.014) 
(Fig. 1A). After 8 weeks on a HFD, histological sections 
of pancreata also showed islet hypertrophy and a sig-
nificant increase in relative islet area in HFD-fed mice 
(1.37 ± 0.12%, n=3) compared with RD-fed mice (0.88 
± 0.12%, n=4, P=0.038) (Fig. 1B and 1C). The biolumi-
nescence intensity observed in the HFD group (n=7) 
increased from 3.53 ± 0.58 × 105 photons/s at week 0 to 
1.41 ± 0.32 × 106 photons/s following 8 weeks of HFD 
administration, likely reflecting an increase in islet area 
(paired t-test, P=0.023) (Fig. 1D and 1E). In contrast, 
there was little change in bioluminescence intensity ob-
served in the control Rd group over this period (6.06 ± 
0.96 × 105 photons/s at week 0 to 7.11 ± 3.13 × 105 
photons/s following 8 weeks).
Next, we examined the ability of BLi to monitor the 
decrease in β-cell mass in two different models of β-cell 
destruction. We first observed a decline in BLI intensity 
following STZ injection into miP-Luc-Vu mice (Fig. 
2a and 2B). By the fourth day after STZ treatment, sig-
nal intensity was reduced by 18.7% (from 4.06 ± 0.49 × 
105 photons/s to 7.60 ± 0.24 × 104 photons/s, n=5). Com-
paring STZ-treated mice with control mice, BLi signal 
was significantly lower in STZ-treated mice at day 4 
(Control: 4.34 ± 1.12 × 105 photons/s, P=0.014). In the 
second set of experiments, we generated Mafa-deficient 
and Mafk-transgenic (Mafa−/−Mafk+) mice that expressed 
the MIP-Luc transgene to monitor the changes in β-cell 
mass in a genetic diabetes models (Fig. 2c and 2d). we 
measured the intensity of the BLi signal in 6 week-old 
MIP-Luc-VU (n=8), Mafa−/−MIP-Luc-VU (n=5), and 
Mafa−/−Mafk+MIP-Luc-VU (n=6) mice following intra-
venous injection of luciferin. Bioluminescence intensity 
in miP-Luc-Vu mice and Mafa−/−miP-Luc-Vu mice 
was 3.81 ± 0.75 × 106 and 2.75 ± 0.11 × 106 photons/s, 
respectively, whereas the signal observed in the Mafa−/−
Mafk+MIP-Luc-VU mice was significantly reduced (2.89 
± 0.99 × 105 photons/s, P=0.0006 vs. wild-type). Im-
munohistochemical analysis of pancreata from the three 
genotypic groups of mice using anti-hormone antibodies 
was performed at 20 weeks of age. consistent with our 
previous findings, there was a reduction in the ratio of β 
to α cells in Mafa−/− mice accompanied by an abnormal 
islet architecture characterized by the presence of sev-
eral non β-cells in the core of the islets. We further ob-
served atrophic islets in Mafa−/−Mafk+ mice owing to 
the loss of β-cells, which were replaced by glucagon-
positive cells (Fig. 2e) [17, 23].
BLI of embryonic β-cell neogenesis
We examined whether embryonic β-cell neogenesis 
could be detected noninvasively by BLi in miP-Luc-Vu 
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mice in utero. BLi of pregnant wild-type icR females 
fertilized by MIP-Luc-VU males first revealed an in 
utero signal at e16.5 (Fig. 3a). although the number of 
individual signals increased during the late gestational 
stage, the signal intensity of the signals did not. in ad-
dition, the signal intensity of individual spots differed 
significantly from 2.7 × 104 to 2.4 × 105 photons/s. The 
luminescence observed in pregnant mice was derived 
solely from the fetuses as demonstrated through the peri-
toneum (Fig. 3B). we observed a total of 15 biolumines-
cence signals in 20 transgene-positive fetuses identified 
by PcR-based genotyping in three pregnant mice, sug-
gesting that the level of detection of fetal pancreas by 
BLI was about 75.0% at E18.5.
Discussion
In this study, we present two novel findings. First, 
diabetic Mafa−/−Mafk+ mice expressing a bioluminescent 
reporter under the control of the insulin promoter exhib-
ited a reduction in signal, reflecting the impaired β-cell 
development in these mice. Second, we were able to use 
Fig. 1. (A) Fasting blood glucose levels of male MIP-Luc-VU mice following 8 weeks of a regular diet (RD) 
or a high fat diet (HFD) (n=7 in each group). (B) Hematoxylin and eosin staining of pancreatic sections 
from mice fed the RD or HFD for 8 weeks. Scale bars indicate 100 µm. (c) islet area relative to total 
pancreas of mice fed the RD (n=4) or HFD (n=3). (D) Representative bioluminescence images of MIP-
Luc-VU mice fed the RD or HFD. (E) Quantification of signal intensity in the RD (n=7) and HFD groups 
(n=7) at 0, 4, and 8 weeks.
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BLI to image fetal β-cell genesis in a noninvasive man-
ner. Other researchers have developed different strains 
of mice carrying a β-cell-specific luciferase reporter that 
permit BLI to quantitate β-cell mass [19, 22]. In contrast 
to other β-cell imaging modalities such as PET and MRI, 
BLI provides quantifiable data with high throughput and 
inherently low background [14].
we also performed BLi of miP-Luc-Vu mice on icR 
background following Virostko’s protocols, in which in 
vivo BLi images were obtained in the right lateral posi-
tion 10 min after intraperitoneal injection of luciferin 
with a dose of 150 mg/kg [21]. Signal intensities of the 
icR transgenic mice at 10 weeks of age showed 1.92 ± 
0.43 × 106 photons/s (n=7). Furthermore, signal intensi-
ties of 25 isolated islets (n=7) following overnight cul-
ture in 11.1 mM glucose showed 6.2 ± 0.21 × 106 
photons/s. These results are quite comparable with pre-
vious results obtained from FVB transgenic mice, sug-
gesting the difference between the icR and FVB ge-
netic background has no significant impact on the 
bioluminescence intensities in miP-Luc-Vu mice [21].
as shown in Fig. 1, miP-Luc-Vu mice fed a hFd for 
only 8 weeks exhibited a significant increase in biolu-
minescence; however feeding of a hFd for 2 months 
Fig. 2. (a) Representative bioluminescence images of 
miP-Luc-Vu mice before (day 0) and after injec-
tion (days 4 and 8) with streptozotocin (STZ, 200 
mg/kg body weight, i.p.). (B) Quantification of 
signal intensity in the vehicle control group (n=5) 
and STZ group (n=5) at 0, 4, and 8 days after 
injection. *P=0.014 vs. Vehicle. (C) Representa-
tive bioluminescence images of miP-Luc-Vu, 
Mafa-deficient MIP-Luc-VU (Mafa−/−miP-Luc-
Vu), and Mafa-deficient, Mafk-transgenic miP-
Luc-Vu (Mafa−/−Mafk+miP-Luc-Vu) mice at 6 
weeks of age. (D) Quantification of signal inten-
sity from MIP-Luc-VU (n=8), Mafa−/−miP-Luc-
VU (n=5), and Mafa−/−Mafk+MIP-Luc-VU (n=6) 
mice. (e) immunohistochemistry of wild-type 
(wT), Mafa−/−, and Mafa−/−Mafk+ mice islets at 
20 weeks of age to detect insulin (ins, green), 
glucagon (glu, red), pancreatic polypeptide (PP, 
red), and somatostatin (SOm, red). Nuclei were 
visualized with 4’,6-diamidino-2-phenylindole 
(daPi, blue). Scale bars indicate 50 µm.
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had no substantial effect on bioluminescence in a previ-
ous study [21]. The difference probably results from the 
fat content in the diet; the content used in this study was 
twice that of the previous study. meanwhile, the increase 
in BLI was substantially more than the increase in β-cell 
area (197 vs. 155%), suggesting that BLi might be in-
fluenced by other factors, including chronic hyperglyce-
mia and inflammatory mediators [16, 21].
Noninvasive imaging and quantification of the β-cell 
mass in vivo has been considered important in basic sci-
ence and clinical studies. a number of human studies 
have shown that both type 1 and type 2 diabetes are 
associated with a significant deficit in β-cell mass [11]. 
Mafa−/−Mafk+ mice display nearly complete lack of β 
cells at birth and have fasting blood glucose levels that 
are more than 500 mg/dl [17]. as shown in Fig. 2, the 
reduction of the BLi signal to background levels in the 
mutant mice was consistent with the lack of insulin-
positive cells observed in this strain.
it has been shown that STZ administration induces 
ins1 transcription in extrapancreatic organs, which could 
be monitored by BLi using mice expressing the lucifer-
ase gene under the control of rat insulin promoter (RiP-
Luc) [6, 9]. we observed here that some but not all miP-
Luc-Vu mice treated with STZ generated a 
bioluminescent signal from the region of the liver [6]. 
although Mafa−/−Mafk+ mice develop a hyperglycemia 
that is comparable to or more severe than that observed 
in the STZ model, these mice did not show any extra-
pancreatic insulin gene expression. The difference be-
tween these results and those of chen et al. might be 
explained by the plausible contribution of large maf 
transcription factors to hyperglycemia-induced insulin 
activation in extrapancreatic regions. indeed, mafa 
regulates ins2 transcription in thymic medullary epithe-
lial cells (mTec), which are necessary for tissue-specif-
ic antigen presentation and negative selection of autore-
active T cells [12].
In the process of β-cell development, fully differenti-
ated β cells first appear around E13 at the start of a mas-
sive wave of endocrine differentiation in the pancreas 
known as the “secondary transition” [15]. in this study, 
we could detect a BLi signal only after the secondary 
transition during E16.5 and E18.5, probably due to an 
insufficient β-cell number and low insulin gene activity 
before E16.5. Visualization of β-cell development in 
primary and early developmental stages in vivo will re-
quire improvement of the imaging device to enable de-
tection of very faint signals in addition to mice express-
ing a more intense bioluminescent reporter. Furthermore, 
we found wide variations between the signal intensities 
from the pregnant animals. This is probably due to the 
position and direction of the fetuses and not to individ-
ual differences in fetal development.
In summary, we demonstrated that alterations in β-cell 
mass and fetal β-cell neogenesis in uteri in MIP-Luc-VU 
mice could be monitored by BLi in a noninvasive man-
ner. BLI using β-cell-specific reporter mice should fa-
cilitate the study of diabetes to gain a better understand-
ing of its pathophysiology and should also be useful for 
drug development and for strategies aiming at β-cell 
regeneration.
Fig. 3. (a) Sequential bioluminescence images of pregnant wild-type females that had been fertilized by miP-Luc-
VU males at embryonic days (E) 14.5, 16.5, and 18.5. The numbers indicate bioluminescence intensity 
(photons/s) from each region of interest. (B) abdominal skin was removed to expose the fetuses to verify 
that all light emission was emanating from the fetuses.
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